Bcl-2 plays a key role instead of mdr1 in the resistance to hexadecylphosphocholine in human epidermoid tumor cell line KB

被引:12
作者
Fu, D [1 ]
Shi, ZX [1 ]
Wang, YZ [1 ]
机构
[1] Inst Radiat Med, Beijing 100850, Peoples R China
关键词
hexadecylphosphocholine; multidrug resistance; bcl-2;
D O I
10.1016/S0304-3835(99)00146-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We induced tolerance to hexadecylphosphocholine (HePC) in the human epidermoid tumor cell line, KB. After 70 weeks of adaptation, the IC50 Of HePC in the resistant cells KBr was 32-fold higher than in parental KB cells, and they were 30-fold more resistant to another ether lipid analogue, ET-18-OCH3. The KBr cells also showed cross-resistance to vincristine and colchicine while remaining sensitive to other chemotherapy agents. RT-PCR assays showed that expression of the multidrug resistance gene (MDR1) was positive in KBr cells, whereas the expression of GST-pi (glutathione S-transferase pi) and MRP (multidrug resistance protein) was undetectable in KBr cells. Both an immunocytochemistry test and Western blot analysis indicated that the expression of bcl-2 in KBr cells was strongly positive, while it was only mildly expressed in KB cells. Verapamil could not reverse the resistance of KBr to HePC although it is a well-known reversing agent against MDR1. Our results suggest that bcl-2 instead of MDR1 plays a major role in the resistance of KBr cells. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:147 / 153
页数:7
相关论文
共 23 条
[1]  
BEKETICORESKOVI.L, 1995, J NATL CANCER I, V45, P1593
[2]   The antiproliferative effect of hexadecylphosphocholine toward HL60 cells is prevented by exogenous lysophosphatidylcholine [J].
Boggs, K ;
Rock, CO ;
Jackowski, S .
BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1998, 1389 (01) :1-12
[3]   TOPICAL ADMINISTRATION OF HEXADECYLPHOSPHOCHOLINE IN PATIENTS WITH CUTANEOUS LYMPHOMAS - RESULTS OF A PHASE-I/II STUDY [J].
DUMMER, R ;
KRASOVEC, M ;
ROGER, J ;
SINDERMANN, H ;
BURG, G .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1993, 29 (06) :963-970
[4]  
Engelmann J, 1996, ANTICANCER RES, V16, P1429
[5]   Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB [J].
Fleer, EAM ;
Berkovic, D ;
Grunwald, U ;
Hiddemann, W .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (03) :506-511
[6]   P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia [J].
Johnston, JB ;
Daeninck, P ;
Verburg, L ;
Lee, K ;
Williams, G ;
Israels, LG ;
Mowat, MRA ;
Begleiter, A .
LEUKEMIA & LYMPHOMA, 1997, 26 (5-6) :435-+
[7]   Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood ALL [J].
Kanerva, J ;
Tiirikainen, M ;
Makipernaa, A ;
Riikonen, P ;
Mottonen, M ;
Salmi, TT ;
Krusius, T ;
Saarinen-Pihkala, UM .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1998, 15 (01) :11-21
[8]  
KAUFMANNKOLLE P, 1994, CANCER CHEMOTH PHARM, V34, P393, DOI 10.1007/s002800050160
[9]  
LINDENBOIM L, 1995, J NEUROCHEM, V64, P1054
[10]   CLINICAL AND PHARMACOLOGICAL STUDY OF MULTIDRUG-RESISTANCE REVERSAL WITH VINBLASTINE AND BEPRIDIL [J].
LINN, SC ;
VANKALKEN, CK ;
VANTELLINGEN, O ;
VANDERVALK, P ;
VANGROENINGEN, CJ ;
KUIPER, CM ;
PINEDO, HM ;
GIACCONE, G .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) :812-819